Tobramycin

Aminoglycoside antibiotic capable of translational readthrough

Phase of research

FDA-/EMA-approved for Cystic Fibrosis

How it helps

Anti-Infective,Restore CFTR Function

General information

N/A

Synonyms

N/A

Marketed as

TOBI Podhaler - prescribing information

Dietary sources

N/A

Structure not available

C₁₈H₃₇N₅O₉

Drug-Mutation Relation

results for D1152H / F508del

See all data on Tobramycin

Treats

Mutation	Link	Tested on	Impact factor	Notes
F508del	Mannitol Does Not Enhance Tobramycin Killing of Pseudomonas aeruginosa in a Cystic Fibrosis Model System of Biofilm Formation	human cell cultures	3.06	Co-treatment with mannitol is not more effective
General effect	Arikace compared to TOBI® in people with CF with chronic Pseudomonas aeruginosa infections (Insmed TR02-108)	humans	N/A	More effective than Amikacin.
General effect	Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial.	humans	3.19	Tobramycin inhalation powder is more convenient than tobramycin inhalation solution.

Does not treat

Mutation	Link	Tested on	Impact factor	Notes